We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.

, , , , , , , , , , , , , , , ,
Journal of Clinical Endocrinology and Metabolism
Erasmus MC: University Medical Center Rotterdam

Muller, A., Davis, R., Zib, K., Scarlett, J., Lamberts, S., Janssen, J., & van der Lely, A.-J. (2001). Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism. Retrieved from http://hdl.handle.net/1765/9570